Minerva Neurosciences (NERV) Tops Q4 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Minerva Neurosciences (NERV) Tops Q4 EPS by 6c

Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results

March 26, 2015 4:01 PM EDT

- MIN-101 Phase 2b trial for schizophrenia on track - - Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD patients also expected to begin in mid-2015 - - Company advancing CNS pipeline with MIN-117 and MIN-301 - - Management to host conference call today at 4:30 p.m. ET -

WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases... More

Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results

March 26, 2015 4:01 PM EDT

- MIN-101 Phase 2b trial for schizophrenia on track - - Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD patients also expected to begin in mid-2015 - - Company advancing CNS pipeline with MIN-117 and MIN-301 - - Management to host conference call today at 4:30 p.m. ET -

WALTHAM, Mass., March 26, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) diseases... More